- Home
- CSBR vs CRVO Comparison
CSBR vs CRVO Comparison
Compare CSBR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- CRVO
- Stock Information
- Founded
- CSBR 1985
- CRVO 2001
- Country
- CSBR United States
- CRVO United States
- Employees
- CSBR N/A
- CRVO N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- CSBR Health Care
- CRVO Health Care
- Exchange
- CSBR Nasdaq
- CRVO Nasdaq
- Market Cap
- CSBR 113.0M
- CRVO 95.4M
- IPO Year
- CSBR 1986
- CRVO N/A
- Fundamental
- Price
- CSBR $6.21
- CRVO $8.49
- Analyst Decision
- CSBR Strong Buy
- CRVO Strong Buy
- Analyst Count
- CSBR 1
- CRVO 8
- Target Price
- CSBR $12.00
- CRVO $25.43
- AVG Volume (30 Days)
- CSBR 42.0K
- CRVO 453.1K
- Earning Date
- CSBR 03-11-2025
- CRVO 05-20-2025
- Dividend Yield
- CSBR N/A
- CRVO N/A
- EPS Growth
- CSBR N/A
- CRVO N/A
- EPS
- CSBR 0.46
- CRVO N/A
- Revenue
- CSBR $58,591,000.00
- CRVO $9,737,974.00
- Revenue This Year
- CSBR $15.11
- CRVO N/A
- Revenue Next Year
- CSBR $7.80
- CRVO N/A
- P/E Ratio
- CSBR $12.94
- CRVO N/A
- Revenue Growth
- CSBR 19.03
- CRVO 36.29
- 52 Week Low
- CSBR $3.60
- CRVO $1.80
- 52 Week High
- CSBR $11.99
- CRVO $25.69
- Technical
- Relative Strength Index (RSI)
- CSBR 36.72
- CRVO 46.29
- Support Level
- CSBR $5.65
- CRVO $8.40
- Resistance Level
- CSBR $8.27
- CRVO $11.79
- Average True Range (ATR)
- CSBR 0.57
- CRVO 0.99
- MACD
- CSBR -0.08
- CRVO -0.19
- Stochastic Oscillator
- CSBR 21.67
- CRVO 10.45
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.